Protocol
Daily multivitamin for cancer prevention
In the Physicians' Health Study II, 14,641 male doctors took a daily multivitamin or placebo An inactive substitute made to look like the real treatment, so participants cannot tell which one they received. for a median of 11 years.
Grade C: human trials exist, but they are small, mixed or not yet repeated. This is not a finding that it does not work. How to read a grade →
At a glance
A long trial followed over 14,000 male doctors for about 11 years. Those who took a daily multivitamin had slightly fewer cancers than those on a dummy pill. The gap was small and only just counted. Prostate and bowel cancer were not lowered. Only men took part.
- What was measured
- New cancers over about 11 years.
- How big
- New cancers were 17.0 against 18.3 per 1,000 men each year.Read from the summary of PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 23162860.
- Who it applies to
- Men aged 50 or older; women were not studied.
- Safety
- None identified.
- Compared with
- A placebo pill.
- Certainty
- Grade C, resting on: One large long-term randomized trial.
- What would change this grade
- Could rise to B with: Randomized trial of a daily multivitamin. Who: Men and women aged 50 or older. Measured: Total cancer incidence. Length: At least 10 years.
- Cost
- No price recorded yet.
- Sources
- 1 study cited on this record, listed under Sources.
- For clinicians
- A one-page summary of this record that prints with a clinician's name and practice, folds to a plain-language patient handout, and gives a chart note to paste into the patient record: Printable summary and chart note.
In the Physicians' Health Study II, 14,641 male doctors took a daily multivitamin or placebo for a median of 11 years. Total cancer was slightly lower with the multivitamin (17.0 against 18.3 per 1,000 person-years, HR 0.92), with a confidence interval The range the true effect probably falls in. A wide interval means the estimate is uncertain. ending at 0.998. Prostate and colorectal cancer were not reduced.
Why this letter
Why this gradeGrade C, small or unreplicated trials. The reasoning, and what the grade does not cover.
Grade C on cancer. One large trial found total cancer 8% lower with a daily multivitamin over 11 years, with a confidence interval just excluding no effect (Gaziano et al., 2012; PMID 23162860).
WHY NOT Bthe effect is small and marginal, it was found in one trial of male physicians, and specific cancers were not reduced.
WHAT THIS GRADE DOES NOT COVERwomen, cognition (tested separately in COSMOS), and high-dose single vitamins. It also does not cover the cancer types that were not reduced, prostate and colorectal, or deaths from cancer, which were not significantly lower.
A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →
Who responds: this record's trial reading reports no subgroup that identifies who responds.
Evidence notes: randomized trial
Endpoint The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score. graded: Total cancer incidence (hard)
Last reviewed: November 2026
The trial that would change this grade.
A positive trial of this shape, supported by further trials, would move this entry to B.
Why the current trials fall short
A replication The same finding reproduced by a separate research group. A result seen once can be chance or bias; a replicated one is harder to explain away. including women would carry it to B.
ClinicalTrials.gov, the public registry run by the U.S. National Library of Medicine, lists studies that are recruiting volunteers. The link below searches it for Vitamins among studies recruiting now. EBL has no relationship with any listed study and receives no payment for this link.
Dose, form and timing
Not applicable; the outcome is cancer.
Safety
No safety data. Each caution on this record, sorted by what it rests on.
None recorded.
None recorded.
None recorded.
None recorded.
No safety data: EBL has found no trial or report of harm for this record. That is an absence of evidence, not a finding of safety.
Grade history
How this letter has changedLatest: No. 467 · November 2026 · First graded.
New record in the gap-report batch. In the Physicians' Health Study II, 14,641 male doctors took a daily multivitamin or placebo for a median of 11 years. Total cancer was slightly lower with the multivitamin (17.0 against 18.3 per 1,000 person-years, HR 0.92), with a confidence interval ending at 0.998. Prostate and colorectal cancer were not reduced.PMID 23162860
Every change to a letter on this site is dated and published. The full evidence log →
Sources
- Citations
- Every paper cited on this page is matched to its PubMed record on every build.
- Retractions
- None of these papers is retracted or under a journal expression of concern. PubMed is checked again on every build.
- Read against the papers
- November 2026. By a language model (AI-assisted reading), not yet reviewed by a clinician.
- Outside review
- Not yet done. No reviewer outside EBL has checked this record.
What each of these checks can and cannot show: evidence integrity.
The evidence, in fullOne paper, linked to its PubMed record.
Gaziano et al. (JAMA, 2012; PMID 23162860): Physicians' Health Study II, randomized placebo-controlled trial, 14,641 US male physicians aged 50 or older, median 11.2 years; total cancer 17.0 against 18.3 events per 1,000 person-years (HR 0.92, 95% CI 0.86 to 0.998); no effect on prostate or colorectal cancer; cancer mortality HR 0.88 (0.77 to 1.01).
How EBL searched for the trials (1 search)
The search that was run, what it returned, and what was left out and why, so the absence of evidence can be checked as well as its presence.
(multivitamin*[tiab]) AND cancer[tiab] AND randomized controlled trial[pt]PubMed watch: does a new study change the grade? (nothing new)
No new paper matching the search behind this grade has been added to PubMed since November 2026.
Last run November 2026. A letter on EBL moves only after a logged review. A new paper never moves a letter by arriving: it is read, the answer is written here, and any change to the letter is published in the evidence log.
For each trial behind a letter on this page, the funding its PubMed record lists. "No funder" means PubMed lists none, not that the trial had no funding.
- Gaziano et al., 2012, JAMA (PMID 23162860): PubMed lists funding from US National Institutes of Health (National Heart, Lung, and Blood Institute); US National Institutes of Health (National Cancer Institute).
Disclosure
Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment. Stopping a prescription is a decision for your physician.
Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy
© Evidence Based Longevity, Inc. All rights reserved
These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.
Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →